TY - JOUR
T1 - Downstream Revenue Generated by a Cancer Genetic Counselor
AU - Mauer, Caitlin B.
AU - Reys, Brian D.
AU - Hall, Reece E.
AU - Campbell, Connor L.
AU - Pirzadeh-Miller, Sara M.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - PURPOSEEnhanced cancer risk reduction measures are recommended for patients with hereditary predispositions to cancer. Providing these services within a healthcare institution (HI) generates downstream revenue (DSR). We evaluated the DSR for our institution after patients were identified to have a pathogenic variant by a genetic counselor (GC).METHODSRetrospective chart review identified patients with hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) seen in the UT Southwestern Medical Center Cancer Genetics Clinic between November 1, 2009, and January 31, 2019. All billable encounters were recorded. Total revenue and work relative value units were calculated after patients met with a GC.RESULTSFour hundred twenty-five patients with HBOC and LS had financial data available for analysis. After GC visit, DSR totaled $32,798,000 in US dollars (USD). Patients unaffected with cancer (n = 176) generated $8,453,000 (USD). Patients (n = 96) whose first visit to the institution were for GC consultation (naïve patients) generated $5,933,000 (USD). Unaffected, naïve patients (n = 64) generated $3,190,000 (USD) in DSR. The 425 total patients generated 73,957 work relative value units at the institution after their appointment with a GC.CONCLUSIONGCs bring in substantial DSR for their HI by identifying patients with HBOC or LS. Institution naïve and unaffected patients who continue care at the institution provide additional opportunities to generate DSR. If applied to additional pathogenic variant carriers, GCs can further increase DSR for an HI.
AB - PURPOSEEnhanced cancer risk reduction measures are recommended for patients with hereditary predispositions to cancer. Providing these services within a healthcare institution (HI) generates downstream revenue (DSR). We evaluated the DSR for our institution after patients were identified to have a pathogenic variant by a genetic counselor (GC).METHODSRetrospective chart review identified patients with hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) seen in the UT Southwestern Medical Center Cancer Genetics Clinic between November 1, 2009, and January 31, 2019. All billable encounters were recorded. Total revenue and work relative value units were calculated after patients met with a GC.RESULTSFour hundred twenty-five patients with HBOC and LS had financial data available for analysis. After GC visit, DSR totaled $32,798,000 in US dollars (USD). Patients unaffected with cancer (n = 176) generated $8,453,000 (USD). Patients (n = 96) whose first visit to the institution were for GC consultation (naïve patients) generated $5,933,000 (USD). Unaffected, naïve patients (n = 64) generated $3,190,000 (USD) in DSR. The 425 total patients generated 73,957 work relative value units at the institution after their appointment with a GC.CONCLUSIONGCs bring in substantial DSR for their HI by identifying patients with HBOC or LS. Institution naïve and unaffected patients who continue care at the institution provide additional opportunities to generate DSR. If applied to additional pathogenic variant carriers, GCs can further increase DSR for an HI.
UR - http://www.scopus.com/inward/record.url?scp=85117541149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117541149&partnerID=8YFLogxK
U2 - 10.1200/OP.20.00464
DO - 10.1200/OP.20.00464
M3 - Article
C2 - 33555913
AN - SCOPUS:85117541149
SN - 2688-1527
VL - 17
SP - E1394-E1402
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 9
ER -